Hemispherx Biopharma Europe Enters Investment Banking Relations with Major European Institutions

Hemispherx Biopharma (Amex: HEB) said today it started the process of a private placement for its subsidiary HEB-EU. HEB-EU, which has a marketing application pending in the European Union (EU) for treatment of Chronic Fatigue Syndrome/Myalgic Encephalitis (CFS/ME), was founded to develop and market certain novel anti-viral products, including Ampligen(R) for untreatable chronic and life-threatening human viral disorders. Quadra Invest and Arthur Anderson Corporate Finance Belgium have been mandated to organize the private placement. Quadra Invest is the venture capital division of Dexia, one of the largest Belgian banks. Arthur Anderson Corporate Finance is a division of Arthur Anderson, a leading professional services organization. In addition, Quadra Invest formally notified HEB-EU that their group would take a percentage of the equity placement into their own corporate account. Jurgen Ingels of Quadra Invest commented: "This investment opportunity is exciting to us -- namely a product on the cusp of commercialization, strong experienced management, and broad patent coverage into a major untapped pharmaceutical market." Terms of the investment were not disclosed. William A. Carter, M.D., Chairman of Hemispherx Europe commented: "We think HEB-EU is uniquely situated to capture a major position in the European pharmaceutical arena, and as a result, to arouse significant investor interest, both at the institutional and individual investor level." Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. ots Original Text Service: Hemispherx Biopharma Internet: http://www.newsaktuell.de Contact: Richard Piani of Hemispherx Biopharma Europe, fax, 331-4624-8075, or William A. Carter, M.D., CEO of Hemispherx Biopharma U.S., 215-988-0080; or Jurgen Ingels of Quadra Invest, fax, 322-222-8308; or Finance - Dries Bossuyt, fax, 322-545-3199, or Investors - Diane Will, 214- 954-9300, fax, 214-954-9333, both of Arthur Anderson Corp. Web site: http://www.hemispherx.com

Klíčová slova PROTEXT-Hemispherx Biopharma

Evropa, EU, NATO (es)


Přihlásit k odběru

Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.